中国全科医学2011，Vol.14Issue(24)：2800-2802,3.
紫杉醇腹腔内灌注联合康莱特治疗晚期肝癌腹腔积液疗效观察
Paclitaxel Intraperitoneal Chemotherapy Combined with Intravenous Kanglaite in Treating Malignant Ascites of Advanced Hepatic Carcinoma
张明智 1张喜爱 1周超锋 1付晓瑞1
作者信息
- 1. 450052河南省郑州市,郑州大学第一附属医院肿瘤科
- 折叠
摘要
Abstract
Objective The aim of this study is to discuss the efficacy and safety of the treatment of malignant ascites in advanced hepatic carcinoma with intraperitoneal Paclitaxel and intravenous Kanglaite. Methods Twenty - four cases of advanced hepatic carcinoma patients with malignant ascites were enrolled and Paclitaxel (60 mg/m2 ) resovled in normal saline (1500 ～2000 ml ) was administered via intraperitoneal injection weekly for 4 weeks. Kanglaite ( 100 ml/d ) was used on the first day of the first chemotherapy cycle for 10 consec:utive days. Short - term efficacy, adverse reactions, and the quality of life were evaluated according to WHO criteria. Results After four treatment cycles, complete remission was seen in 9 ( 37.5％ ) out of the 24 patients and partial remission was observed in 8 ( 33.3％ ) cases, with a total effective rate of 70.8％ . Quality of life was improved remarkably in 9 ( 36.0％ ) cases and improved in 14 ( 58.3％ ) cases. Grade Ⅰ～Ⅱ leucopenia was noted in 20 cases,grade Ⅰ～Ⅲ abdominal pain was found in 9 cases, and another 3 cases suffered from grade Ⅰ～Ⅱ nausea and vomiting. Conclusion Intraperitoneal chemotherapy of Paclitaxel combined with intravenous Kanglaite is effective and relatively safe in treating malignant ascites of adavanced hepatic carcinoma, which improves the therapeutic effects, reduces the side effects of chemotherapy, and improves the quality of life of the patients.关键词
紫杉醇/输注,胃肠外/康莱特/肝肿瘤/腹腔积液Key words
Paclitaxel/ Infusions, parenteral/ Kanglaite/ Liver neoplasms/ Ascites分类
医药卫生引用本文复制引用
张明智,张喜爱,周超锋,付晓瑞..紫杉醇腹腔内灌注联合康莱特治疗晚期肝癌腹腔积液疗效观察[J].中国全科医学,2011,14(24):2800-2802,3.
